|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for LGALS9 |
 Gene summary |
| Basic gene Info. | Gene symbol | LGALS9 |
| Gene name | lectin, galactoside-binding, soluble, 9 | |
| Synonyms | HUAT|LGALS9A | |
| Cytomap | UCSC genome browser: 17q11.2 | |
| Type of gene | protein-coding | |
| RefGenes | NM_002308.3, NM_009587.2,NR_024043.1, | |
| Description | ecalectingal-9galectin 9galectin-9tumor antigen HOM-HD-21urate transporter/channel protein | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 601879 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000168961 | ||
| HPRD : 03528 | ||
| Vega : OTTHUMG00000179831 | ||
| Protein | UniProt: O00182 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_LGALS9 | |
| BioGPS: 3965 | ||
| Pathway | NCI Pathway Interaction Database: LGALS9 | |
| KEGG: LGALS9 | ||
| REACTOME: LGALS9 | ||
| Pathway Commons: LGALS9 | ||
| Context | iHOP: LGALS9 | |
| ligand binding site mutation search in PubMed: LGALS9 | ||
| UCL Cancer Institute: LGALS9 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for LGALS9 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | R65 | R65W | BLCA | 1 | R271 | R271H | COAD | 1 | N280 | R279H | GBM | 1 | N63,R65 | P64L | LUAD | 1 | W82 | G83V | LUAD | 1 | R292 | R292Q | SKCM | 1 | W82 | G80E | SKCM | 1 | R271,N269 | P270S | SKCM | 1 | E85 | P84L | SKCM | 1 | N137 | S135F | SKCM | 1 | N137 | G138D | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for LGALS9 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | R271 | P270S | -1.4700243 | N269 | P270S | -1.4700243 | R271 | R271H | -1.2943698 | R65 | R65W | -1.0532841 | R292 | R292Q | -0.78706457 | N280 | R279H | -0.7710568 | N137 | S135F | -0.65348864 | W82 | G83V | -0.48708285 | N137 | G138D | -0.41694456 | R65 | P64L | -0.35852927 | N63 | P64L | -0.35852927 | E85 | P84L | -0.26541965 | W82 | G80E | -0.075118792 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for LGALS9 from PDB |
| Top |
| Differential gene expression and gene-gene network for LGALS9 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for LGALS9 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0027697 | Nephritis | 1 | Therapeutic |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for LGALS9 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Experimental | DB04472 | (R)-1-Para-Nitro-Phenyl-2-Azido-Ethanol | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of LGALS9 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | GAL | BETA-D-GALACTOSE | 2zhk | A | N137 | GAL | BETA-D-GALACTOSE | 2zhl | B | N137 | GAL | BETA-D-GALACTOSE | 2zhl | C | N137 | GAL | BETA-D-GALACTOSE | 2zhm | B | N137 | GAL | BETA-D-GALACTOSE | 2zhm | D | N137 | LBT | ALPHA-LACTOSE | 2eak | A | N63 R65 W82 E85 | LBT | ALPHA-LACTOSE | 2eak | C | N63 R65 W82 E85 | GAL | BETA-D-GALACTOSE | 2zhk | A | N63 R65 W82 E85 | GAL | BETA-D-GALACTOSE | 2zhk | B | N63 R65 W82 E85 | GAL | BETA-D-GALACTOSE | 2zhl | A | N63 R65 W82 E85 | GAL | BETA-D-GALACTOSE | 2zhl | B | N63 R65 W82 E85 | GAL | BETA-D-GALACTOSE | 2zhl | C | N63 R65 W82 E85 | GAL | BETA-D-GALACTOSE | 2zhl | D | N63 R65 W82 E85 | GAL | BETA-D-GALACTOSE | 2zhm | A | N63 R65 W82 E85 | GAL | BETA-D-GALACTOSE | 2zhm | B | N63 R65 W82 E85 | GAL | BETA-D-GALACTOSE | 2zhm | C | N63 R65 W82 E85 | GAL | BETA-D-GALACTOSE | 2zhm | D | N63 R65 W82 E85 | GAL | BETA-D-GALACTOSE | 2zhn | A | N63 R65 W82 E85 | LAT | BETA-LACTOSE | 3lse | A | N63 R65 W82 E85 | LSE | 2-(TRIMETHYLSILYL)ETHYL 4-O-BETA-D-GALACTOPYRANOSYL-6- SE-METHYL-6-SELENO-BETA-D-GLUCOPYRANOSIDE | 3wlu | A | N63 R65 W82 E85 | LSE | 2-(TRIMETHYLSILYL)ETHYL 4-O-BETA-D-GALACTOPYRANOSYL-6- SE-METHYL-6-SELENO-BETA-D-GLUCOPYRANOSIDE | 3wlu | B | N63 R65 W82 E85 | LSE | 2-(TRIMETHYLSILYL)ETHYL 4-O-BETA-D-GALACTOPYRANOSYL-6- SE-METHYL-6-SELENO-BETA-D-GLUCOPYRANOSIDE | 3wlu | C | N63 R65 W82 E85 | LSE | 2-(TRIMETHYLSILYL)ETHYL 4-O-BETA-D-GALACTOPYRANOSYL-6- SE-METHYL-6-SELENO-BETA-D-GLUCOPYRANOSIDE | 3wlu | D | N63 R65 W82 E85 | GAL | BETA-D-GALACTOSE | 3wv6 | A | N63 R65 W82 E85 | GAL | BETA-D-GALACTOSE | 3wv6 | B | N63 R65 W82 E85 | GAL | BETA-D-GALACTOSE | 2eal | A | R65 E85 | GAL | BETA-D-GALACTOSE | 2eal | B | R65 E85 | BGC | BETA-D-GLUCOSE | 3wv6 | A | R65 E85 | BGC | BETA-D-GLUCOSE | 3wv6 | B | R65 E85 |
| Top |
| Conservation information for LBS of LGALS9 |
| Multiple alignments for O00182 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |